Sherlock Bio Links With Danaher’s IDT to Supply its CRISPR-Based Coronavirus Test

Source: FierceBiotech

Sherlock Biosciences will team up with Danaher’s Integrated DNA Technologies division to scale up the manufacturing of its CRISPR-based coronavirus diagnostic test in the coming weeks, according to a FierceBiotech report.

The rapid test is designed to provide a COVID-19 result in about an hour, without specialized laboratory equipment. It received an emergency authorization from the FDA in early May as the first diagnostic to employ the gene-editing technology.

Read the full article.

Related Content